share_log

Relief Therapeutics' Subsidiary Posts Early Data For Nasal Spray COVID-19 Treatment

Relief Therapeutics' Subsidiary Posts Early Data For Nasal Spray COVID-19 Treatment

缓解治疗公司的子公司发布了鼻喷剂新冠肺炎治疗的早期数据
Benzinga Real-time News ·  2021/10/27 09:07
  • Relief Therapeutics Holding SA's (OTC:RLFTF) wholly-owned subsidiary, APR Applied Pharma Research SA, has reported interim results from its clinical trial of nasal spray Sentinox in COVID-19.
  • Relief also reported that data from the study suggest that Sentinox could effectively reduce the SARS-CoV-2 viral load at the level of the nasal mucosa.
  • The interim analysis, based on 30 patients, showed that all patients treated with Sentinox tested negative for SARS-CoV-2 by the end of the study period (Day 21). 
  • By contrast, one out of 10 patients in the control group was still positive by Day 21. 
  • A post-market, confirmatory, interventional, randomized, placebo-controlled study is expected to enroll a total of 57 patients. 
  • The study will assess the efficacy and safety of Sentinox spray in reducing viral load in the upper respiratory airways of recently infected SARS-CoV-2 individuals.
  • Sentinox is an acid-oxidizing solution (AOS) containing hypochlorous acid at 0.005%. 
  • The device is intended for irrigation, cleaning, and moistening nasal cavities.
  • Related: Why NRX Pharmaceuticals (NRXP) Stock Is Moving Friday?
  • Price Action: RLFTF stock closed 6.28% higher at $0.091 on Tuesday.
  • 救济治疗公司持有SA‘s(场外交易代码：RLFTF)全资子公司，应用药学研究协会，已经报告了其在新冠肺炎进行的鼻喷剂Sentinox临床试验的中期结果。
  • Release还报道说，研究数据表明，Sentinox可以有效地降低鼻黏膜水平的SARS-CoV-2病毒载量。
  • 这项基于30名患者的中期分析显示，在研究结束时(第21天)，接受Sentinox治疗的所有患者的SARS-CoV-2检测结果均为阴性。
  • 相比之下，对照组中每10名患者中就有一名在第21天时仍呈阳性。
  • 一项上市后的验证性、干预性、随机化、安慰剂对照研究预计将招募57名患者。
  • 这项研究将评估Sentinox喷雾剂在降低最近感染SARS-CoV-2患者上呼吸道病毒载量方面的有效性和安全性。
  • 森替诺是一种含有0.005%次氯酸的酸性氧化液。
  • 该设备用于冲洗、清洁和润湿鼻腔。
  • 相关： 为什么NRX制药公司(NRX PharmPharmticals)的股票周五会上涨？
  • 价格行动：RLFTF股票周二收高6.28%，报0.091美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发